{"columns":["node_id","class_id","agent","route","formulation","dose","unit","frequency","dosing_strategy","component_ratio","label","note","is_template"],"rows":[["SEMA_SC_0p5MG_QW","GLP1_LA","semaglutide","SC",null,"0.5","mg","QW","fixed",null,"semaglutide 0.5 mg subcutaneous once weekly",null,"no"],["SEMA_SC_1p0MG_QW","GLP1_LA","semaglutide","SC",null,"1.0","mg","QW","fixed",null,"semaglutide 1.0 mg subcutaneous once weekly",null,"no"],["SEMA_SC_2p0MG_QW","GLP1_LA","semaglutide","SC",null,"2.0","mg","QW","fixed",null,"semaglutide 2.0 mg subcutaneous once weekly",null,"no"],["SEMA_SC_2p4MG_QW","GLP1_LA","semaglutide","SC",null,"2.4","mg","QW","fixed",null,"semaglutide 2.4 mg subcutaneous once weekly",null,"no"],["SEMA_SC_7p2MG_QW","GLP1_LA","semaglutide","SC",null,"7.2","mg","QW","fixed",null,"semaglutide 7.2 mg subcutaneous once weekly",null,"no"],["SEMA_PO_3MG_QD","GLP1_ORAL_PEP","semaglutide","PO","original tablet","3","mg","QD","fixed",null,"semaglutide 3 mg oral once daily (original tablet)","A prespecified sensitivity analysis pools 3 mg with reformulated 1.5 mg; 7 mg with 4 mg; and 14 mg with 9 mg only.","no"],["SEMA_PO_7MG_QD","GLP1_ORAL_PEP","semaglutide","PO","original tablet","7","mg","QD","fixed",null,"semaglutide 7 mg oral once daily (original tablet)","A prespecified sensitivity analysis pools 3 mg with reformulated 1.5 mg; 7 mg with 4 mg; and 14 mg with 9 mg only.","no"],["SEMA_PO_14MG_QD","GLP1_ORAL_PEP","semaglutide","PO","original tablet","14","mg","QD","fixed",null,"semaglutide 14 mg oral once daily (original tablet)","A prespecified sensitivity analysis pools 3 mg with reformulated 1.5 mg; 7 mg with 4 mg; and 14 mg with 9 mg only.","no"],["SEMAR2_PO_1p5MG_QD","GLP1_ORAL_PEP","semaglutide","PO","reformulated tablet","1.5","mg","QD","fixed",null,"semaglutide 1.5 mg oral once daily (reformulated tablet)","Bioequivalent to original tablet 3 mg. Pooled with SEMA_PO_3MG_QD only in the prespecified sensitivity analysis.","no"],["SEMAR2_PO_4MG_QD","GLP1_ORAL_PEP","semaglutide","PO","reformulated tablet","4","mg","QD","fixed",null,"semaglutide 4 mg oral once daily (reformulated tablet)","Bioequivalent to original tablet 7 mg. Pooled with SEMA_PO_7MG_QD only in the prespecified sensitivity analysis.","no"],["SEMAR2_PO_9MG_QD","GLP1_ORAL_PEP","semaglutide","PO","reformulated tablet","9","mg","QD","fixed",null,"semaglutide 9 mg oral once daily (reformulated tablet)","Bioequivalent to original tablet 14 mg. Pooled with SEMA_PO_14MG_QD only in the prespecified sensitivity analysis.","no"],["SEMA_PO_25MG_QD","GLP1_ORAL_PEP","semaglutide","PO","higher dose oral program","25","mg","QD","fixed",null,"semaglutide 25 mg oral once daily (higher dose oral program)",null,"no"],["SEMA_PO_50MG_QD","GLP1_ORAL_PEP","semaglutide","PO","higher dose oral program","50","mg","QD","fixed",null,"semaglutide 50 mg oral once daily (higher dose oral program)",null,"no"],["SEMA_PO_FLEX_QD","GLP1_ORAL_PEP","semaglutide","PO","original tablet",null,null,"QD","flexible",null,"semaglutide oral once daily (original tablet), flexible dose: 3, 7 or 14 mg adjusted by HbA1c and tolerability","For example PIONEER 7. Sensitivity analysis assigns the arm to 14 mg. A flexible regimen with a different formulation, permitted dose set or adjustment algorithm is a different node.","no"],["LIRA_SC_0p6MG_QD","GLP1_LA","liraglutide","SC",null,"0.6","mg","QD","fixed",null,"liraglutide 0.6 mg subcutaneous once daily",null,"no"],["LIRA_SC_1p2MG_QD","GLP1_LA","liraglutide","SC",null,"1.2","mg","QD","fixed",null,"liraglutide 1.2 mg subcutaneous once daily",null,"no"],["LIRA_SC_1p8MG_QD","GLP1_LA","liraglutide","SC",null,"1.8","mg","QD","fixed",null,"liraglutide 1.8 mg subcutaneous once daily",null,"no"],["LIRA_SC_3p0MG_QD","GLP1_LA","liraglutide","SC",null,"3.0","mg","QD","fixed",null,"liraglutide 3.0 mg subcutaneous once daily",null,"no"],["LIRA_SC_FLEX_QD","GLP1_LA","liraglutide","SC","pen 6 mg/mL",null,null,"QD","flexible",null,"liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability","Sensitivity analysis assigns the arm to 1.8 mg. A flexible regimen with a different permitted dose set or algorithm is a different node.","no"],["DULA_SC_0p75MG_QW","GLP1_LA","dulaglutide","SC",null,"0.75","mg","QW","fixed",null,"dulaglutide 0.75 mg subcutaneous once weekly",null,"no"],["DULA_SC_1p5MG_QW","GLP1_LA","dulaglutide","SC",null,"1.5","mg","QW","fixed",null,"dulaglutide 1.5 mg subcutaneous once weekly",null,"no"],["DULA_SC_3p0MG_QW","GLP1_LA","dulaglutide","SC",null,"3.0","mg","QW","fixed",null,"dulaglutide 3.0 mg subcutaneous once weekly",null,"no"],["DULA_SC_4p5MG_QW","GLP1_LA","dulaglutide","SC",null,"4.5","mg","QW","fixed",null,"dulaglutide 4.5 mg subcutaneous once weekly",null,"no"],["EXEN_SC_5UG_BID","GLP1_SA","exenatide","SC",null,"5","ug","BID","fixed",null,"exenatide 5 ug subcutaneous twice daily",null,"no"],["EXEN_SC_10UG_BID","GLP1_SA","exenatide","SC",null,"10","ug","BID","fixed",null,"exenatide 10 ug subcutaneous twice daily",null,"no"],["EXENER_SC_2MG_QW","GLP1_LA","exenatide extended release","SC",null,"2","mg","QW","fixed",null,"exenatide extended release 2 mg subcutaneous once weekly",null,"no"],["EXENIMP_IMPLANT_20UG_CONT","GLP1_LA","exenatide (ITCA 650 implant)","IMPLANT",null,"20","ug","CONT","fixed",null,"exenatide (ITCA 650 implant) 20 ug implant continuous","Dose per day.","no"],["EXENIMP_IMPLANT_60UG_CONT","GLP1_LA","exenatide (ITCA 650 implant)","IMPLANT",null,"60","ug","CONT","fixed",null,"exenatide (ITCA 650 implant) 60 ug implant continuous","Dose per day.","no"],["LIXI_SC_20UG_QD","GLP1_SA","lixisenatide","SC",null,"20","ug","QD","fixed",null,"lixisenatide 20 ug subcutaneous once daily",null,"no"],["ALBI_SC_30MG_QW","GLP1_LA","albiglutide","SC",null,"30","mg","QW","fixed",null,"albiglutide 30 mg subcutaneous once weekly","Withdrawn from the market in 2018 for commercial reasons.","no"],["ALBI_SC_50MG_QW","GLP1_LA","albiglutide","SC",null,"50","mg","QW","fixed",null,"albiglutide 50 mg subcutaneous once weekly","Withdrawn from the market in 2018 for commercial reasons.","no"],["TASP_SC_10MG_QW","GLP1_LA","taspoglutide","SC",null,"10","mg","QW","fixed",null,"taspoglutide 10 mg subcutaneous once weekly","Development discontinued.","no"],["TASP_SC_20MG_QW","GLP1_LA","taspoglutide","SC",null,"20","mg","QW","fixed",null,"taspoglutide 20 mg subcutaneous once weekly","Development discontinued.","no"],["EFPE_SC_2MG_QW","GLP1_LA","efpeglenatide","SC",null,"2","mg","QW","fixed",null,"efpeglenatide 2 mg subcutaneous once weekly",null,"no"],["EFPE_SC_4MG_QW","GLP1_LA","efpeglenatide","SC",null,"4","mg","QW","fixed",null,"efpeglenatide 4 mg subcutaneous once weekly",null,"no"],["EFPE_SC_6MG_QW","GLP1_LA","efpeglenatide","SC",null,"6","mg","QW","fixed",null,"efpeglenatide 6 mg subcutaneous once weekly",null,"no"],["PEGLOX_SC_0p1MG_QW","GLP1_LA","polyethylene glycol loxenatide","SC",null,"0.1","mg","QW","fixed",null,"polyethylene glycol loxenatide 0.1 mg subcutaneous once weekly",null,"no"],["PEGLOX_SC_0p2MG_QW","GLP1_LA","polyethylene glycol loxenatide","SC",null,"0.2","mg","QW","fixed",null,"polyethylene glycol loxenatide 0.2 mg subcutaneous once weekly",null,"no"],["BEIN_SC_0p1MG_TID","GLP1_SA","beinaglutide","SC",null,"0.1","mg","TID","fixed",null,"beinaglutide 0.1 mg subcutaneous three times daily",null,"no"],["BEIN_SC_0p2MG_TID","GLP1_SA","beinaglutide","SC",null,"0.2","mg","TID","fixed",null,"beinaglutide 0.2 mg subcutaneous three times daily",null,"no"],["TIRZ_SC_1MG_QW","GIP_GLP1","tirzepatide","SC",null,"1","mg","QW","fixed",null,"tirzepatide 1 mg subcutaneous once weekly",null,"no"],["TIRZ_SC_5MG_QW","GIP_GLP1","tirzepatide","SC",null,"5","mg","QW","fixed",null,"tirzepatide 5 mg subcutaneous once weekly",null,"no"],["TIRZ_SC_10MG_QW","GIP_GLP1","tirzepatide","SC",null,"10","mg","QW","fixed",null,"tirzepatide 10 mg subcutaneous once weekly",null,"no"],["TIRZ_SC_15MG_QW","GIP_GLP1","tirzepatide","SC",null,"15","mg","QW","fixed",null,"tirzepatide 15 mg subcutaneous once weekly",null,"no"],["TIRZ_SC_MTD_QW","GIP_GLP1","tirzepatide","SC","single dose pen or vial",null,null,"QW","maximum_tolerated",null,"tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg","For example SURMOUNT-5. Sensitivity analysis assigns the arm to 15 mg. A different permitted dose set is a different node.","no"],["RETA_SC_0p5MG_QW","TRIPLE","retatrutide","SC",null,"0.5","mg","QW","fixed",null,"retatrutide 0.5 mg subcutaneous once weekly",null,"no"],["RETA_SC_1MG_QW","TRIPLE","retatrutide","SC",null,"1","mg","QW","fixed",null,"retatrutide 1 mg subcutaneous once weekly",null,"no"],["RETA_SC_4MG_QW","TRIPLE","retatrutide","SC",null,"4","mg","QW","fixed",null,"retatrutide 4 mg subcutaneous once weekly",null,"no"],["RETA_SC_8MG_QW","TRIPLE","retatrutide","SC",null,"8","mg","QW","fixed",null,"retatrutide 8 mg subcutaneous once weekly",null,"no"],["RETA_SC_12MG_QW","TRIPLE","retatrutide","SC",null,"12","mg","QW","fixed",null,"retatrutide 12 mg subcutaneous once weekly",null,"no"],["SURV_SC_0p3MG_QW","GCG_GLP1","survodutide","SC",null,"0.3","mg","QW","fixed",null,"survodutide 0.3 mg subcutaneous once weekly",null,"no"],["SURV_SC_0p6MG_QW","GCG_GLP1","survodutide","SC",null,"0.6","mg","QW","fixed",null,"survodutide 0.6 mg subcutaneous once weekly",null,"no"],["SURV_SC_0p9MG_QW","GCG_GLP1","survodutide","SC",null,"0.9","mg","QW","fixed",null,"survodutide 0.9 mg subcutaneous once weekly",null,"no"],["SURV_SC_1p8MG_QW","GCG_GLP1","survodutide","SC",null,"1.8","mg","QW","fixed",null,"survodutide 1.8 mg subcutaneous once weekly",null,"no"],["SURV_SC_2p4MG_QW","GCG_GLP1","survodutide","SC",null,"2.4","mg","QW","fixed",null,"survodutide 2.4 mg subcutaneous once weekly",null,"no"],["SURV_SC_2p7MG_QW","GCG_GLP1","survodutide","SC",null,"2.7","mg","QW","fixed",null,"survodutide 2.7 mg subcutaneous once weekly",null,"no"],["SURV_SC_3p6MG_QW","GCG_GLP1","survodutide","SC",null,"3.6","mg","QW","fixed",null,"survodutide 3.6 mg subcutaneous once weekly",null,"no"],["SURV_SC_4p8MG_QW","GCG_GLP1","survodutide","SC",null,"4.8","mg","QW","fixed",null,"survodutide 4.8 mg subcutaneous once weekly",null,"no"],["SURV_SC_6p0MG_QW","GCG_GLP1","survodutide","SC",null,"6.0","mg","QW","fixed",null,"survodutide 6.0 mg subcutaneous once weekly",null,"no"],["MAZD_SC_3MG_QW","GCG_GLP1","mazdutide","SC",null,"3","mg","QW","fixed",null,"mazdutide 3 mg subcutaneous once weekly",null,"no"],["MAZD_SC_4MG_QW","GCG_GLP1","mazdutide","SC",null,"4","mg","QW","fixed",null,"mazdutide 4 mg subcutaneous once weekly",null,"no"],["MAZD_SC_4p5MG_QW","GCG_GLP1","mazdutide","SC",null,"4.5","mg","QW","fixed",null,"mazdutide 4.5 mg subcutaneous once weekly",null,"no"],["MAZD_SC_6MG_QW","GCG_GLP1","mazdutide","SC",null,"6","mg","QW","fixed",null,"mazdutide 6 mg subcutaneous once weekly",null,"no"],["MAZD_SC_9MG_QW","GCG_GLP1","mazdutide","SC",null,"9","mg","QW","fixed",null,"mazdutide 9 mg subcutaneous once weekly",null,"no"],["COTA_SC_100UG_QD","GCG_GLP1","cotadutide","SC",null,"100","ug","QD","fixed",null,"cotadutide 100 ug subcutaneous once daily",null,"no"],["COTA_SC_200UG_QD","GCG_GLP1","cotadutide","SC",null,"200","ug","QD","fixed",null,"cotadutide 200 ug subcutaneous once daily",null,"no"],["COTA_SC_300UG_QD","GCG_GLP1","cotadutide","SC",null,"300","ug","QD","fixed",null,"cotadutide 300 ug subcutaneous once daily",null,"no"],["EFINO_SC_10MG_QW","GCG_GLP1","efinopegdutide","SC",null,"10","mg","QW","fixed",null,"efinopegdutide 10 mg subcutaneous once weekly",null,"no"],["PEMV_SC_1p2MG_QW","GCG_GLP1","pemvidutide","SC",null,"1.2","mg","QW","fixed",null,"pemvidutide 1.2 mg subcutaneous once weekly",null,"no"],["PEMV_SC_1p8MG_QW","GCG_GLP1","pemvidutide","SC",null,"1.8","mg","QW","fixed",null,"pemvidutide 1.8 mg subcutaneous once weekly",null,"no"],["PEMV_SC_2p4MG_QW","GCG_GLP1","pemvidutide","SC",null,"2.4","mg","QW","fixed",null,"pemvidutide 2.4 mg subcutaneous once weekly",null,"no"],["ORFO_PO_3MG_QD","GLP1_ORAL_SM","orforglipron","PO",null,"3","mg","QD","fixed",null,"orforglipron 3 mg oral once daily",null,"no"],["ORFO_PO_6MG_QD","GLP1_ORAL_SM","orforglipron","PO",null,"6","mg","QD","fixed",null,"orforglipron 6 mg oral once daily",null,"no"],["ORFO_PO_12MG_QD","GLP1_ORAL_SM","orforglipron","PO",null,"12","mg","QD","fixed",null,"orforglipron 12 mg oral once daily",null,"no"],["ORFO_PO_24MG_QD","GLP1_ORAL_SM","orforglipron","PO",null,"24","mg","QD","fixed",null,"orforglipron 24 mg oral once daily",null,"no"],["ORFO_PO_36MG_QD","GLP1_ORAL_SM","orforglipron","PO",null,"36","mg","QD","fixed",null,"orforglipron 36 mg oral once daily",null,"no"],["ORFO_PO_45MG_QD","GLP1_ORAL_SM","orforglipron","PO",null,"45","mg","QD","fixed",null,"orforglipron 45 mg oral once daily",null,"no"],["DANU_PO_40MG_BID","GLP1_ORAL_SM","danuglipron","PO",null,"40","mg","BID","fixed",null,"danuglipron 40 mg oral twice daily",null,"no"],["DANU_PO_80MG_BID","GLP1_ORAL_SM","danuglipron","PO",null,"80","mg","BID","fixed",null,"danuglipron 80 mg oral twice daily",null,"no"],["DANU_PO_120MG_BID","GLP1_ORAL_SM","danuglipron","PO",null,"120","mg","BID","fixed",null,"danuglipron 120 mg oral twice daily",null,"no"],["DANU_PO_160MG_BID","GLP1_ORAL_SM","danuglipron","PO",null,"160","mg","BID","fixed",null,"danuglipron 160 mg oral twice daily",null,"no"],["DANU_PO_200MG_BID","GLP1_ORAL_SM","danuglipron","PO",null,"200","mg","BID","fixed",null,"danuglipron 200 mg oral twice daily",null,"no"],["CAGSEMA_SC_2p4_2p4MG_QW","AMY_GLP1","cagrilintide and semaglutide","SC",null,"2.4/2.4","mg","QW","fixed","cagrilintide 2.4 mg; semaglutide 2.4 mg","cagrilintide and semaglutide 2.4/2.4 mg subcutaneous once weekly",null,"no"],["ECNO_SC_<dose>_QW","GLP1_LA","ecnoglutide","SC",null,"<dose>","mg","QW","fixed",null,"ecnoglutide <dose> mg subcutaneous once weekly","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["AMYC_SC_<dose>_QW","AMY_GLP1","amycretin (zenagamtide)","SC",null,"<dose>","mg","QW","fixed",null,"amycretin (zenagamtide) <dose> mg subcutaneous once weekly","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["AMYC_PO_<dose>_QD","AMY_GLP1","amycretin (zenagamtide)","PO",null,"<dose>","mg","QD","fixed",null,"amycretin (zenagamtide) <dose> mg oral once daily","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["MARI_SC_<dose>_Q4W","GIPR_ANT_GLP1","maridebart cafraglutide","SC",null,"<dose>","mg","Q4W","fixed",null,"maridebart cafraglutide <dose> mg subcutaneous every 4 weeks","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["VK2735_SC_<dose>_QW","GIP_GLP1","VK2735","SC",null,"<dose>","mg","QW","fixed",null,"VK2735 <dose> mg subcutaneous once weekly","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["VK2735_PO_<dose>_QD","GIP_GLP1","VK2735","PO",null,"<dose>","mg","QD","fixed",null,"VK2735 <dose> mg oral once daily","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["HRS9531_SC_<dose>_QW","GIP_GLP1","HRS9531","SC",null,"<dose>","mg","QW","fixed",null,"HRS9531 <dose> mg subcutaneous once weekly","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["HRS7535_PO_<dose>_QD","GLP1_ORAL_SM","HRS-7535","PO",null,"<dose>","mg","QD","fixed",null,"HRS-7535 <dose> mg oral once daily","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["LOTI_PO_<dose>_QD","GLP1_ORAL_SM","lotiglipron","PO",null,"<dose>","mg","QD","fixed",null,"lotiglipron <dose> mg oral once daily","Template, not a node: excluded from every network until a numeric randomized maintenance dose replaces <dose> at extraction.","yes"],["IDEGLIRA_SC_TIT_QD","INS_GLP1_FRC","insulin degludec and liraglutide (IDegLira)","SC",null,null,null,"QD","titrated_to_target","insulin degludec 100 U and liraglutide 3.6 mg per mL (maximum 50 dose steps: 50 U and 1.8 mg)","insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated",null,"no"],["IGLARLIXI2_SC_TIT_QD","INS_GLP1_FRC","insulin glargine and lixisenatide (iGlarLixi)","SC","pen 100 U insulin glargine and 50 ug lixisenatide per mL",null,null,"QD","titrated_to_target","2 U per 1 ug (10 to 40 U pen)","iGlarLixi 2:1 pen subcutaneous once daily titrated","Used throughout the trial. Combined with the other iGlarLixi nodes only in a prespecified sensitivity analysis.","no"],["IGLARLIXI3_SC_TIT_QD","INS_GLP1_FRC","insulin glargine and lixisenatide (iGlarLixi)","SC","pen 100 U insulin glargine and 33 ug lixisenatide per mL",null,null,"QD","titrated_to_target","3 U per 1 ug (30 to 60 U pen)","iGlarLixi 3:1 pen subcutaneous once daily titrated","Used throughout the trial. Combined with the other iGlarLixi nodes only in a prespecified sensitivity analysis.","no"],["IGLARLIXI_SWITCH_<strategy>_SC_TIT_QD","INS_GLP1_FRC","insulin glargine and lixisenatide (iGlarLixi)","SC","2:1 and 3:1 pens with switching",null,null,"QD","titrated_to_target","switching between the 2:1 and 3:1 pens","iGlarLixi with pen switching subcutaneous once daily titrated (strategy <strategy>)","Switching strategy template, not a node: excluded from every network until a unique strategy identifier; the permitted pens; the switching threshold and the titration algorithm are recorded. Each distinct strategy is its own node. Combined with IGLARLIXI2_SC_TIT_QD and IGLARLIXI3_SC_TIT_QD only in a sensitivity analysis.","yes"],["ICOSEMA_SC_TIT_QW","INS_GLP1_FRC","insulin icodec and semaglutide (IcoSema)","SC",null,null,null,"QW","titrated_to_target","insulin icodec 700 U and semaglutide 2 mg per mL (350 U per 1 mg)","insulin icodec and semaglutide (IcoSema) subcutaneous once weekly titrated","Titrated by the trial algorithm up to the labeled maximum.","no"],["PLACEBO","PLACEBO","placebo",null,null,null,null,null,"fixed",null,"placebo",null,"no"],["STANDARD_CARE","STANDARD_CARE","standard care or no added treatment",null,null,null,null,null,"fixed",null,"standard care or no added treatment",null,"no"],["LIFESTYLE","LIFESTYLE","lifestyle intervention (randomized arm)",null,null,null,null,null,"fixed",null,"lifestyle intervention (randomized arm)",null,"no"],["SURGERY","SURGERY","bariatric or metabolic surgery",null,null,null,null,null,"fixed",null,"bariatric or metabolic surgery","Eligible comparator; enters a network only when transitivity can be supported.","no"],["METFORMIN","MET","metformin",null,null,null,null,null,"fixed",null,"metformin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["GLIMEPIRIDE","SU","glimepiride",null,null,null,null,null,"titrated_to_target",null,"glimepiride","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["GLIPIZIDE","SU","glipizide",null,null,null,null,null,"titrated_to_target",null,"glipizide","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["GLICLAZIDE","SU","gliclazide",null,null,null,null,null,"titrated_to_target",null,"gliclazide","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["GLIBENCLAMIDE","SU","glibenclamide",null,null,null,null,null,"titrated_to_target",null,"glibenclamide","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["PIOGLITAZONE","TZD","pioglitazone",null,null,null,null,null,"fixed",null,"pioglitazone","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["ROSIGLITAZONE","TZD","rosiglitazone",null,null,null,null,null,"fixed",null,"rosiglitazone","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["SITAGLIPTIN","DPP4I","sitagliptin",null,null,null,null,null,"fixed",null,"sitagliptin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["LINAGLIPTIN","DPP4I","linagliptin",null,null,null,null,null,"fixed",null,"linagliptin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["SAXAGLIPTIN","DPP4I","saxagliptin",null,null,null,null,null,"fixed",null,"saxagliptin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["VILDAGLIPTIN","DPP4I","vildagliptin",null,null,null,null,null,"fixed",null,"vildagliptin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["ALOGLIPTIN","DPP4I","alogliptin",null,null,null,null,null,"fixed",null,"alogliptin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["EMPAGLIFLOZIN","SGLT2I","empagliflozin",null,null,null,null,null,"fixed",null,"empagliflozin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["DAPAGLIFLOZIN","SGLT2I","dapagliflozin",null,null,null,null,null,"fixed",null,"dapagliflozin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["CANAGLIFLOZIN","SGLT2I","canagliflozin",null,null,null,null,null,"fixed",null,"canagliflozin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["ERTUGLIFLOZIN","SGLT2I","ertugliflozin",null,null,null,null,null,"fixed",null,"ertugliflozin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["ACARBOSE","AGI","acarbose",null,null,null,null,null,"fixed",null,"acarbose","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["REPAGLINIDE","GLINIDE","repaglinide",null,null,null,null,null,"fixed",null,"repaglinide","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["NATEGLINIDE","GLINIDE","nateglinide",null,null,null,null,null,"fixed",null,"nateglinide","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_GLARGINE","INS_BASAL","insulin glargine",null,null,null,null,null,"titrated_to_target",null,"insulin glargine","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_DEGLUDEC","INS_BASAL","insulin degludec",null,null,null,null,null,"titrated_to_target",null,"insulin degludec","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_DETEMIR","INS_BASAL","insulin detemir",null,null,null,null,null,"titrated_to_target",null,"insulin detemir","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_NPH","INS_BASAL","NPH insulin",null,null,null,null,null,"titrated_to_target",null,"NPH insulin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_ICODEC","INS_BASAL","insulin icodec",null,null,null,null,null,"titrated_to_target",null,"insulin icodec","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_ASPART","INS_PRANDIAL","insulin aspart (prandial)",null,null,null,null,null,"titrated_to_target",null,"insulin aspart (prandial)","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_LISPRO","INS_PRANDIAL","insulin lispro (prandial)",null,null,null,null,null,"titrated_to_target",null,"insulin lispro (prandial)","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_GLULISINE","INS_PRANDIAL","insulin glulisine (prandial)",null,null,null,null,null,"titrated_to_target",null,"insulin glulisine (prandial)","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_REGULAR","INS_PRANDIAL","regular human insulin (prandial)",null,null,null,null,null,"titrated_to_target",null,"regular human insulin (prandial)","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["INS_PREMIX","INS_PREMIX","premixed insulin",null,null,null,null,null,"titrated_to_target",null,"premixed insulin","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["ORLISTAT","AOM_OTHER","orlistat",null,null,null,null,null,"fixed",null,"orlistat","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["PHEN_TOPI","AOM_OTHER","phentermine and topiramate",null,null,null,null,null,"fixed",null,"phentermine and topiramate","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["NALT_BUPR","AOM_OTHER","naltrexone and bupropion",null,null,null,null,null,"fixed",null,"naltrexone and bupropion","Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.","no"],["OTHER_ACTIVE_<name>","OTHER_ACTIVE","other active comparator",null,null,null,null,null,"fixed",null,"other active comparator","Comparator template, not a node: excluded from every network until an identified molecule or procedure and its class replace <name>. Doses of that comparator are not separate nodes.","yes"]]}